POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER).
Potassium is the major intracellular cation; it is essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride dissociates in solution to provide potassium ions and chloride ions.
| Metabolism | Potassium is not metabolized; it is primarily excreted by the kidneys (about 90%), with the remainder excreted in feces and small amounts in sweat. Renal excretion is regulated by aldosterone, acid-base balance, and potassium intake. |
| Excretion | Renal: >90% as potassium ion, with minimal biliary or fecal elimination (less than 10% total). |
| Half-life | Not applicable; potassium is a physiologic ion without classic elimination half-life. Steady-state distribution occurs within 6-8 hours of continuous infusion. Clinical context: half-life of potassium is determined by cellular uptake and renal excretion, with rapid redistribution in hypokalemic states. |
| Protein binding | Negligible (<2%); not significantly bound to plasma proteins. |
| Volume of Distribution | 0.5-0.7 L/kg; distributes predominantly in extracellular fluid, with gradual cellular uptake influenced by insulin and acid-base status. |
| Bioavailability | Oral: 90-100% as potassium chloride; IV: 100% (by definition). |
| Onset of Action | Intravenous: immediate (within minutes) for cardiac electrophysiologic effects; oral: 1-2 hours for increase in serum potassium. |
| Duration of Action | Intravenous: 2-4 hours after infusion for serum level elevation, but cellular repletion may require longer; oral: sustained effect over 6-12 hours. Clinical notes: Duration depends on dose, renal function, and degree of deficit. |
40 mEq intravenously over 4-6 hours, as needed. Maximum infusion rate: 10 mEq/hour, maximum concentration: 40 mEq/L.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment; GFR 10-50 mL/min: reduce dose by 25-50% and monitor serum potassium; GFR < 10 mL/min: avoid or use with extreme caution with dose reduction of at least 50%. |
| Liver impairment | No specific Child-Pugh based adjustments; monitor potassium levels due to risk of hyperkalemia in severe hepatic impairment. |
| Pediatric use | 0.25-0.5 mEq/kg/dose intravenously over 4-6 hours, up to 40 mEq/dose. Maximum infusion rate: 0.5 mEq/kg/hour. Dilute to ≤ 40 mEq/L. |
| Geriatric use | Start with lower doses (e.g., 20 mEq) and titrate slowly; monitor renal function and serum potassium frequently due to age-related decline in GFR. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER).
| Breastfeeding | Potassium chloride is a normal component of breast milk. Maternal supplementation does not significantly alter milk concentrations; infant exposure is minimal. M/P ratio: not applicable. |
| Teratogenic Risk | Potassium chloride is a normal constituent of body fluids. At therapeutic doses, no teratogenic effects have been reported. In overdose (hyperkalemia), fetal arrhythmias and death may occur. |
| Fetal Monitoring |
■ FDA Black Box Warning
Potassium chloride injections are concentrated and must be diluted before use. Accidental direct injection or infusion of undiluted potassium chloride can be fatal. Do not administer unless diluted and patient has adequate urine flow.
| Serious Effects |
["Hyperkalemia (serum potassium >5.5 mEq/L)","Severe renal impairment with oliguria or anuria","Adrenal insufficiency (Addison's disease)","Concurrent use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride)","Dehydration or heat cramps","Use of solid oral forms in patients with esophageal compression or delayed gastrointestinal transit"]
| Precautions | ["Risk of hyperkalemia: monitor serum potassium levels frequently, especially in patients with renal impairment, diabetes, or concurrent use of ACE inhibitors, ARBs, potassium-sparing diuretics, or other potassium-elevating drugs.","Cardiac effects: hyperkalemia can cause cardiac arrhythmias, including fatal ventricular fibrillation. ECG monitoring is recommended.","Use with caution in patients with cardiac disease, renal insufficiency, or conditions predisposing to hyperkalemia.","Extravasation: intravenous administration can cause phlebitis and tissue necrosis if extravasation occurs.","Avoid in patients with metabolic acidosis unless corrected."] |
Loading safety data…
| Maternal serum potassium, renal function (BUN/creatinine), ECG for signs of hyper- or hypokalemia, fetal heart rate monitoring if maternal electrolyte disturbance is present. |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. |